Akademska digitalna zbirka SLovenije - logo
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • Evaluating telehealth for t...
    Naumann, Leonie; Reul-Hirche, Hildegard; Comans, Tracy; Burns, Clare L.; Paratz, Jenny; Cottrell, Michelle

    Supportive care in cancer, 04/2023, Letnik: 31, Številka: 4
    Journal Article

    Purpose The primary aim of this study was to compare the attendance rates at a group lymphoedema education and same-day individual surveillance appointment between telehealth (TH) and in-person (IP) care for participants following breast cancer (BC) surgery. Secondary aims included evaluating participant satisfaction and costs between the two service models, while also determining the extent of technical issues and clinician satisfaction towards TH. Methods Participants following axillary lymph node dissection surgery attended a group lymphoedema education and same-day 1:1 monitoring session via their preferred mode (TH or IP). Attendance rates, satisfaction and costs were recorded for both cohorts, and technical disruption and clinician satisfaction for the TH cohort. Results Fifty-five individuals participated. All 28 participants who nominated the IP intervention attended, while 22/27 who nominated the TH intervention attended an appointment. Overall reported participant experience was positive with no significant differences between cohorts. All TH appointments were successfully completed. Clinicians reported high satisfaction for delivery of education (median = 4IQR 4–5) and individual assessment (median = 4IQR 3–4) via TH. Median attendance costs per participant were Australian $39.68 (Q1–Q3 $28.52–$68.64) for TH and Australian $154.26 (Q1–Q3 $81.89–$251.48) for the IP cohort. Conclusion Telehealth-delivered lymphoedema education and assessment for individuals following BC surgery was associated with favourable satisfaction, cost savings and minimal technical issues despite lower attendance than IP care. This study contributes to the growing evidence for TH and its potential applicability to other populations where risk for cancer-related lymphoedema exists.